
From: Kari Rodriguez <Kari.Rodriguez@noridian.com>
Sent: Monday, June 13, 2022 11:01 AM
To: Laxmaiah Manchikanti, MD
Subject: RE: Percutaneous Adhesiolysis CPT 62264 and 62263

Some people who received this message don't often get email from kari.rodriguez@noridian.com. [Learn why this is important](#)
Good afternoon,

Thank you for your inquiry. Percutaneous Adhesiolysis (62264 and 62263) is not addressed in the epidural policy. Noridian currently does not have a specific policy in place for the services you are inquiring on. In the absence of a policy, services would fall under the normal Medicare criteria of needing to be considered reasonable and necessary for a patient in order to be considered for coverage.

Thank you.



Kari Rodriguez
Medical Policy Specialist II, Medical Policy
Noridian Healthcare Solutions LLC
kari.rodriguez@noridian.com | www.noridiansolutions.com

ENABLE ACCESS TO CARE, ELIMINATE BARRIERS, ELEVATE PEOPLE.

From: Laxmaiah Manchikanti, MD <drcm@asipp.org>
Sent: Wednesday, May 25, 2022 8:52 AM
To: Arthur Lurvey <Arthur.Lurvey@noridian.com>; CMD <Medicalpolicy@noridian.com>; Eileen Moynihan <Eileen.Moynihan@noridian.com>
Subject: Percutaneous Adhesiolysis CPT 62264 and 62263

WARNING: This is an external email.
Do not click links or open attachments unless you recognize the sender and know the content is safe.

American Society of Interventional Pain Physicians®
"The Voice of Interventional Pain Management"
81 Lakeview Drive, Paducah, KY 42001
Phone: (270) 554-5394 - Fax: (270) 554-5394
www.asipp.org

May 25, 2022

Arthur N. Lurvey, MD, FACP, FACE
Noridian, LLC
Contractor Medical Director
900 42nd Street S
P.O. Box 6722
Fargo, ND 58108-6722
Arthur.Lurvey@noridian.com; medicalpolicy@noridian.com

Eileen M. Moynihan, M.D., FACP, FACRH
Noridian, LLC
Contractor Medical Director
900 42nd Street S
PO Box 6781
Fargo, ND 58103-6781
eileen.moynihan@noridian.com

Re: Percutaneous Adhesiolysis CPT 62264 and 62263

Dear Contractor Medical Directors of Noridian LLC:

Thank you for development of epidural and facet joint intervention policies. As you recall, in the Epidural Multijurisdictional CAC Committee Meeting, evidence for percutaneous adhesiolysis was considered with a positive response with presence of positive evidence qualifying for coverage inclusion. However, we were informed by CGS that it was not included in the policy; but coverage continues.

Several members in Noridian jurisdiction have contacted us with the coverage issue. Would you please clarify your coverage policy on percutaneous adhesiolysis in managing chronic low back and lower extremity pain?

If you desire, ASIPP, along with state societies, will be happy to provide appropriate peer-reviewed literature on this subject.

Thank you again for your consideration of this matter.

Laxmaiah Manchikanti, MD
Chairman of the Board and Chief Executive Officer, ASIPP, SIPMS
Co-Founder and Director, Pain Management Centers of America
Medical Director, Pain Management Centers of America – Paducah, Marion & Hopkinsville
Ambulatory Surgery Center and Pain Care Surgery Center
Clinical Professor, Anesthesiology and Perioperative Medicine
University of Louisville, Kentucky
Professor of Anesthesiology-Research
Department of Anesthesiology, School of Medicine
LSU Health Sciences Center
2831 Lone Oak Road
Paducah, KY 42003
270-554-8373 ext. 4101
drm@asipp.org

Sheri L. Albers, DO
President, ASIPP
Radiology Research and Consultation
2178 Morley Way
Sacramento, CA 95864

865-300-6284

Sla2oz@aol.com

Amol Soin, MD

Immediate Past President, ASIPP

President, SIPMS

CEO, Ohio Society of Interventional Pain Physicians

Ohio Pain Clinic

7076 Corporate Way, Suite 201

Centerville, OH 45459

937-434-2226

drsoin@gmail.com

Confidentiality Notice - This communication and any attachments are for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, distribution or copying is prohibited. If you are not the intended recipient(s), please contact the sender by replying to this e-mail and destroy/delete all copies of this e-mail message.